Decipher Test Emerges as Key Predictor for Chemotherapy Benefit in Metastatic Prostate Cancer
/in Retrospective studies/by MaxStatins Linked to Improved Survival in Advanced Prostate Cancer Patients on Apalutamide
/in Post-hoc, Retrospective studies/by MaxNutrition and Inflamation: New Research Unveils Five Universal Patient Clusters in Oncology
/in Retrospective studies/by MaxFracture Risk in Prostate Cancer: Insights from a STAMPEDE Trial Analysis on ADT and Zoledronic Acid
/in Retrospective studies/by MaxReal-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/in Retrospective studies/by MaxRetrospective Study On Real World Data: Sipuleucel-T Shows Encouraging Results in mCRPC
/in Retrospective studies/by MaxReal-World Prostate Cancer Treatments Are Better Than Clinical Trial Results, Study Finds
/in Retrospective studies/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/in Post-hoc, Retrospective studies/by MaxNew Study Reveals Key Factors That Influence How Quickly Prostate Cancer Becomes Resistant to Hormone Therapy
/in Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026
- UPDATE: SL-28 Phase 1/2 Trial Started To Recruit in Advanced Solid Tumors July 23, 2026